anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The study is a randomized, double-blind, sham-controlled cross-over trial to assess the efficacy as well as safety and tolerability of auditory SWS enhancement on measured outcomes in PD patients with disturbed nighttime sleep. Patients will be randomized to 2 groups: Group 1 will first be treated with auditory stimulation for 3 nights and then - after a wash-out period of 4 nights - switched to 3 nights of sham stimulation. Group 2 will first receive sham-stimulation for 3 nights and then switch to 3 nights of auditory stimulation treatment. The wash-out period in between will be 4 nights. Patients and investigators assessing the outcomes will be blinded to the conditions. All interventions will take place at the patients' homes.

The pilot study is aimed at assessment of safety, tolerability, feasibility and efficacy of auditory SWS enhancement on measured outcomes in MCI and HD patients with disturbed nighttime sleep. Patients will be treated with verum or sham auditory stimulation for 2 consecutive nights. All interventions will take place at the patients' homes.
FIELD: medicine. ^ SUBSTANCE: group of inventions refers to veterinary science, and concerns inactivated chimeric vaccines and related methods of application. Substance of the inventions involves an inactivated chimeric flavivirus containing a first flavivirus representing a yellow fever virus in which nucleotide sequences coding pre-membrane and membrane proteins are substituted by nucleotide sequences coding pre-membrane and membrane proteins a second flavivirus representing a West Nile fever virus. The inventions also involve an immunogenic composition and a vaccine for protection of animals from the flavivirus infections, involving the inactivated chimeric flavivirus. ^ EFFECT: development of the advanced immunogenic composition and the vaccine on the basis of the inactivated chimeric flavivirus. ^ 14 cl, 3 ex, 5 tbl
PROBLEM TO BE SOLVED: To provide an input method for electronic medical record for efficiently and exactly preparing a medical record by selecting a treatment action routine example file according to the symptom of a patient, sorting out sentences in the selected treatment action routine example file and describing the sorted- out sentences in a prescribed file. SOLUTION: A doctor selects the patient of a hospital ward to send an indication (S2). An indication input picture and a treatment item selection picture are displayed by patients. Any treatment item is selected out of the treatment item selection picture and indicated contents are inputted to the instruction input picture by the input device of the electronic medical record (S3). At such a time, a sentence example file is registered in advance and any indication sentence example is selected out of the sentence example file (S5). At a server computer, the indicated contents are recorded by sections of treatment items, stored in related recording files by patients and related recording files by sections and recorded on a hard disk or the like (S6).
Participants in the control group received standard care (verbal information about procedure and a short written information about the procedure) and no intervention (virtual reality or Therapeutic Touch) was performed. Both groups were re-evaluated using the same scales after the intrauterine insemination. Within 5 minutes of completing the procedure, participants will asked to evaluate their pain in order to characterize pain intensity using the visual analogue scale, anxiety scale and satisfaction scale.
Patients receive atezolizumab IV over about 30-60 minutes every 2 weeks, cobimetinib PO daily for 3 weeks on, 1 week off for 4 weeks of the safety lead-in course. Patients then receive atezolizumab IV over about 30-60 minutes every 2 weeks, cobimetinib PO daily for 3 weeks on, 1 week off, and eribulin IV over 2-5 minutes on days 1 and 8 of cycles 1-4. Cycles 1-4 repeat every 21 days and subsequent cycles with atezolizumab and cobimetinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
PURPOSE:To obtain the titled substance, by contacting an erythropoietin-containing substance such as urine of the patient of anemia with a specific adsorbent to adsorb erythropoietin, eluting the adsorbed erythropoietin, and subjecting the collected fraction to a gel-filtration to remove the polymeric fraction. CONSTITUTION:A composition containing erythropoietin (EPO) (e.g. urine of healthy man, urine of the patient of anemia, treated products thereof, supernatant liquid of the cultured product of an EPO-producing cell, etc.) is made to contact with an adsorbent obtained by bonding a monoclonal anti-EPO antibody obtained from a hydridoma cell prepared by the cell fusion of a myeloma cell and a spleen cell of an experimental animal immuized with EPO. The EPO is adsorbed to the adsorbent by this process. The adsorbed EPO is eluted to obtain an EPO fraction as an adsorbed fraction, and the fraction is subjected to the gel- filtration. The polymeric fraction is removed to botain a high-purity EPO in high efficiency. The EPO is a drug applicable widely to a patients of anemia, post- operative patient, nephrectomized patient under artificial dialysis, etc.
Since the eye is an superficial organ, it has excellent access to ultrasound. Also, the eye has a liquid-filled structure (vitreous body), it is suitable for obtaining some important findings with bedside ultrasound. In patients who visit an emergency room with ocular symptoms, point-of-care ultrasound can quickly identify several emergency diseases. While training of eye ultrasound skills is useful for emergency physicians, hands-on education is risky in pandemic situation such as COVID19. As a solution to this, non-face-to-face education via online has been on the rise. The investigators hypothesized that even an online education is enough to perform basic eye ultrasound by emergency physician.
The iCBT program consists of weekly online lessons, weekly homework assignments, regular automatic email reminders about lessons and homework, weekly contact via phone or email with a CBT therapist, and access to a large online library of written resources about depression and anxiety and application of CBT skills. The CBT therapist contacts all participants once a week to review lessons, assist patients with treatment difficulties, reinforce progress and encourage continued engagement with the program. Therapist-patient contact is limited to 10 minutes per patient per week.
OBJECTIVE: To summarize the FITT (frequency, intensity, time, type), components of exercise programs included in randomized controlled trials (RCTs) that compared 2 or more programs for managing rotator cuff-related shoulder pain (RCRSP). DESIGN: Scoping review. LITERATURE SEARCH: Electronic searches were conducted up to May 2023. STUDY SELECTION CRITERIA: RCTs comparing the effects of 2 or more types of exercise programs, differing in prescription according to the FITT principle, in people with RCRSP. DATA SYNTHESIS: We extracted data from each trial report so that we could answer items 1 to 10 and 13 to 15 from the Consensus on Exercise Reporting Template (CERT). Descriptive analysis of the exercise programs was performed by summarizing and presenting the FITT characteristics, and other relevant CERT characteristics (material, provider, delivery, tailoring). RESULTS: FITT characteristics from 46 exercise programs included in 22 trials were extracted. The exercise programs were divided into 4 categories (defined in accordance to the original authors' description and proposed rationale): motor control (n = 8), scapula-focused (n = 7), eccentric (n = 8), and nonspecific exercise programs (n = 28). Five programs were allocated to 2 different categories. The different program types had similar parameters. Exercise programs frequency ranged from 2 to 7 times per week, dose ranged from 1 to 3 sets and 4 to 30 repetitions per sets, and exercise program duration ranged from 4 to 16 weeks. CONCLUSION: There was considerable variability in the parameters used to prescribe exercises for RCRSP. Clinicians seeking guidance on FITT parameters derived from trials should do so cautiously because there was no one-size-fits-all approach. J Orthop Sports Phys Ther 2024;54(8):513-529. Epub 4 June 2024. doi:10.2519/jospt.2024.12452.
NEW MATERIAL:An anti-malignant neoplastic agent containing the hot-water extract of the bark of Japanese bead tree as an active component. USE:Useful as a remedy of malignant tumor. For example, the agent exhibits excellent suppressing effect to sarcoma 180 ascites carcinoma, scirrhous cancer, p388 mouse leukemia, etc. PROCESS:Bark of Japanese bead tree (Melia azedarach L., Melia azedarach L. var toosendan, etc.) is extracted with water or a polar organic solvent, or extracted successively with a polar organic solvent and water at room temperature as pretreatment. The extraction residue is further extracted with hot water to obtain an extract having low impurity content. The extract may be purified by alcohol precipitation or by dialysis. The extract is prepared to a pharmaceutical preparation by conventional method, and administered parenterally by subcutaneous injection, intravenous injection or intramuscular injetion or orally in the form of tablet, powder, etc. Dose: about 1-5g daily for a male adult.
FIELD: radiology and diagnostics. SUBSTANCE: invention aims at preparing physiologically acceptable  68 Ga solution adequate for diagnostics application. Generator of invention contains  68 Ge (parent radionuclide), zirconium dioxide-doped titanium dioxide (sorbent), and weak hydrogen chloride solutions for sorbing  68 Ge and eluating  68 Ga. Generator is characterized by long service life, high yield of  68 Ga, small breakthrough of  68 Ga, and no necessity in diluting eluate. EFFECT: facilitated procedure. 3 ex
PURPOSE:To provide a vaginal suppository having good absorbability on mucosa, especially vaginal mucosa, not having a mucosa-irritating property, having excellent stability and useful for treating endometriosis by containing danazol and a polyoxyethylene alkyl ether. CONSTITUTION:A suppository contains 1 pt.wt. of danazol and 0.1-20 pts.wt. preferably 0.2-5 pts.wt. of a polyoxyethylene alkyl ether, preferably polyoxyethylene stearyl ether or polyoxyethylene oleyl ether addition-reacted with >=15 moles of ethylene oxide. The suppository is further compounded with a molding agent such as cacao fat, hard fat, laurin fat, glycerol monopalmitate or glycerogelatin and a viscosity-adjusting agent such as glycerol, polyoxyethylene glycol having an average mol.wt. of <=600, propylene glycol or medium chain fatty acid triglyceride.
Based on a review of the literature, the Food and Drug Administration (FDA) concluded that more data are needed regarding the serious risks of misuse, abuse, addiction, overdose, and death associated with the long-term use of extended release/long acting (ER/LA) opioid analgesics. Thus, the FDA is requiring that ER/LA opioid analgesic drug sponsors conduct post-marketing studies to assess these risks. The four observational post-marketing requirement (PMR) studies are labeled Study #2065-1, Study #2065-2, Study #2065-3, and Study #2065-4.

The objective of PMR Study #2065-4 is to define and validate "doctor/pharmacy shopping" as outcomes suggestive of misuse, abuse and/or addiction.

Study #2065-4 consists of three sub-studies, Study 4A, Study 4B, and Study 4C. In the current study (#2065 sub-study, Study 4A), the IMS® LRx database, a longitudinal pharmacy database that captures both third-party and self-pay transactions, will be linked to the PharMetrics Plus™ database, which contains provider, facility and pharmacy claims. From these databases, patients with shopping behavior will be identified and evaluated against an algorithm for abuse/addiction that will be developed and validated in PMR Study #2065-3B. Study #2065-3B will review the literature for health information suggestive of abuse/addiction in medical charts and medical claims. Then, through iterative processes that involve experts reviewing claims profiles and medical charts, text searches of medical records using natural language processing and supervised machine learning will identify and create a compilation of codes and health information with the best specificity and sensitivity to identify patients with opioid abuse/addiction. The compilation of codes and health information will be used to develop the algorithm that Study 4A will apply to define abuse/addiction. Restricting the validation of shopping behavior to only patients with diagnoses related to abuse would ignore the population with undiagnosed abuse. By supplementing ICD-9 codes with other information available on claims (e.g., addiction treatments, emergency visits) to define abuse/addiction, the measurement bias will be decreased and the estimates of the association of shopping behavior with abuse/addiction will be more valid. Categories of doctor shopping will be derived from the population distributions of the multiple variables analyzed for opioid users. The 4 categories will range from no shopping behavior (lowest level) to extensive shopping behavior (most extreme). The specifics of how the categories will be defined will be driven by the data.
Based on data in 38 HPP patients, the pharmacokinetics of asfotase alfa exhibit dose proportionality across the dose range of 0.3 mg/kg to 3 mg/kg once every other day (three times a week) and appear to be time-independent. Steady state exposure was achieved as early as three weeks after the administration of the first dose. The elimination half-life following subcutaneous administration was approximately 5 days.

Table 6 summarizes the pharmacokinetic parameters following multiple doses in 20 HPP patients after subcutaneous administration of STRENSIQ at 2 mg/kg three times per week in Study 2 (age of less than or equal to 5 years) and Study 3 (age of greater than 5 to 12 years), indicating the pharmacokinetics were similar between patients in the two age groups.

Population PK analysis of asfotase alfa concentrations supports weight-based dosing because body weight is a major covariate of asfotase alfa clearance. The formulation concentration had an impact on the systemic exposure of asfotase alfa in HPP patients. The higher concentration formulation (80 mg/0.8 mL vial) achieved an approximately 25% lower systemic asfotase alfa exposure (i.e., concentrations and AUC) compared to the lower concentration formulations (18 mg/0.45 mL, 28 mg/0.7 mL or 40 mg/mL vials) at the same dose of STRENSIQ [see Dosage and Administration (2.2)].

Anti-Drug Antibody Effects on Pharmacokinetics

Formation of anti-drug antibodies resulted in reduced systemic exposure of asfotase alfa.
This study aims to determine the characteristics and distribution of pathogenic bacteria in bloodstream infections (BSIs) by gram-negative bacteria in adults. One hundred seventy-one adult patients with BSIs who were treated at the Affiliated Hospital of Chengde Medical College between January 2018 and January 2020 were included in this study. The patients were assigned to the young- and middle-aged group and elderly group based on age. General patient data were analyzed. More elderly patients had BSIs and gram-negative bacteria than young- and middle-aged patients. The incidence of underlying diseases in elderly patients was significantly higher than the young- and middle-aged patients (P < .01). The composition of Brucella spp. was significantly different between the elderly group and young- and middle-aged group (P < .05). There were significantly more gallbladder infections in the elderly group than the young- and middle-aged group, and significantly fewer elderly patients had no definite infection sites than the young- and middle-aged group (P < .05). The incidence of complications and in-hospital mortality in the elderly group was higher than the young- and middle-aged group (P < .05). BSIs caused by gram-negative bacteria mainly involved elderly patients. BSIs were characterized by complications and a poor prognosis, as well as pathogenic bacteria and primary infection sites.
Surgical prehabilitation aims to optimise patients' physiological reserves to better withstand the stress of surgery, reduce the risk of postoperative complications, and promote a faster and optimal recovery. The purpose of this commentary is to outline the key aspects of prehabilitation before surgery for cancer which seem to impact its effectiveness and wider implementation. Particular attention is paid to the role and integration of resistance training programmes as a key component of multimodal prehabilitation for patients with cancer. We firstly analyse some of the barriers currently hindering the implementation of prehabilitation programmes in the National Health Service (United Kingdom). Later, we describe essential aspects of resistance training design, such as exercise modality and order execution, volume and intensity, rest periods between sets or exercises, and workout frequency. Furthermore, we propose a methodology to use the perception of effort to control patients' progression during a prehabilitation programme.
These group patients will be monitored with ECG, pulse oximetry and noninvasive blood pressure. Anesthesia will be induced using 2-2.5 mg/kg propofol, 1-2 mcg/kg fentanyl, 10 mg-20 mg rocuronium and a proper size laryngeal mask airway will be placed to secure the airway. The lungs will be ventilated with a mixture of 50% and 50% oxygen. After than an ankle block will be performed in patient group block patients using a mixture of 5 ml of 2% lidocaine and 10 ml of 0.5 bupivacaine the same amount placebo (saline) in group placebo under the guidance of peripheral nerve stimulator then the anesthesia will be disconnected and LMA will be removed. The patients will be transferred from postoperative care unit toward after they are eligible for discharge according to the modified scoring system.
Aerosol spray formulations capable of delivering high concentratio of active agent-containing materials and/or excipient are described herein. The formulation contains a carrier fluid, a propellant, and a therapeutic, prophylactic, cosmeticeutical and/or inert solid suspended, dissolved, or dispersed in the formulation. The active ingredient may be any pharmaceutically active agent, but is preferably an antibiotic, an antihistamine, an anesthetic, an anti-inflammatory, and/or an astringent. In one embodiment, the active agent is an antifungal agent. In another embodiment, the active agent is a cosmeticeutical. The active agent can optionally be dispersed on, or associated with, a carrier powder. The carrie fluid is a highly volatile silicone liquid, which evaporates in less than 10 minutes, preferably less than 5 minutes, after application of the formulatio to the patient's skin. The formulation may also contain one or more pharmaceutically acceptable excipients such as antioxidants, stabilizers, perfumes, colorants, viscosifiers, emulsifiers, surfactants, and combination thereof. The formulation can be packaged in a conventional aerosol spray can.
Methods are provided for modulating hematopoietic cell activity comprising modulating the level or activity of ets-related gene (Erg) polypeptide or a transcriptional target of Erg polypeptide or a downstream effector of Erg polypeptide activity. Hematopoietic cells also include erthrocytes and leukocytes. Hematopoietic cells include hematopoietic stem cells (HSCs) and hematopoietic progenitor cells. Hematopoietic cell activity includes one or more functions including homing, engrafting, survival, self-renewal and differentiation. Methods are also provided for screening for modulators of hematopoietic cell activity. Modulators based inter alia on Erg gene-silencing or the administration of Erg polypeptide-encoding sequences are also described.
The invention discloses the new application in a kind of the kidney invigorating teeth consolidating Chinese medicine composition preparation treatment medicine for treating osteoporosis, Chinese medicine composition is made up of following Chinese medicine: Radix Rehmanniae Preparata, Radix Rehmanniae, Caulis Spatholobi, Placenta Hominis, salt Rhizoma Drynariae, Radix Rhapontici, wine Radix Salviae Miltiorrhizae, wine Fructus Schisandrae Chinensis, Rhizoma Dioscoreae, vinegar Radix Curcumae, Radix Astragali Preparata, Radix Achyranthis Bidentatae, Flos Chrysanthemi Indici, Poria, Fructus Lycii, Cortex Moutan, Rhizoma Alismatis (processeded with salt), Cortex Cinnamomi；Its manufacture method comprises the following steps: S1. weighs wine Fructus Schisandrae Chinensis, wine Radix Salviae Miltiorrhizae, Radix Rhapontici, Radix Astragali Preparata, Radix Achyranthis Bidentatae in proportion, standby with ethanol extraction；S2. under remainder, each component Chinese medicine powder is broken into coarse powder, sterilizing；S3. by the coarse powder in step S2 and amalgamation liquid mixing in step S1, dry cream is made；S4. after broken for dried cream powder, dried cream powder is prepared；Soft material the most processed；S6. prepared soft material is made element ball.The pharmacological evaluation of the Chinese medicine composition of the present invention and clinical experiment confirm that its treatment osteoporosis has good effect, and applicable crowd's scope is wide, has wide medical promotional value.
PURPOSE:To obtain a hair growth agent, comprising a senegose and having excellent promoting effects on hair growth and high safety and a cosmetic for hair of the head containing the hair growth agent therein. CONSTITUTION:This hair growth agent comprises a senegose expressed by the formula (R1 and R2 each is H or a short-chain acyl). This cosmetic for hair of the head is prepared by using one or two or more kinds of the hair growth agent as an active ingredient in an amount of 0.01-10wt.%, preferably 1-10wt.% based on the total amount of the cosmetic. The senegose expressed by the formula is extracted from senegas (Polygala senega or Polygala senega L. var. latifolia Torrey et Gray) of the family Polygalaceae which are medicinal plants. The cosmetic for the hair of the head is obtained by suitably blending hydrocarbons, waxes, fats and oils, esters, higher fatty acids, alcohols, surfactants, perfumes, coloring matters, preservatives, antioxidants, ultraviolet light absorbers, pH adjustors, etc. The cosmetic can be applied as a hair cream, hair lotion, a hair tonic, a hair liquid, a pomade, a scalp toning lotion, a shampoo, a rinse, a hair conditioner, a hair spray, etc.
The Brain Health Group (BHG) meets at the same frequency as the GLB-TBI (i.e., 22 group-based sessions, 12 weekly, 4 bi-monthly, and 6 monthly).The focus of the BHG is on brain health education, self-management, and problem-solving and the BHG did not receive any education on weight-loss strategies. Sessions will be delivered in a group setting via telehealth (Microsoft Teams).